帕瑞昔布钠对腹部感染脓毒症患者肠道屏障功能的影响

Weiwei Wu, Yue-Jun Xu, Yue Zou, Caixiang Jin
{"title":"帕瑞昔布钠对腹部感染脓毒症患者肠道屏障功能的影响","authors":"Weiwei Wu, Yue-Jun Xu, Yue Zou, Caixiang Jin","doi":"10.3760/CMA.J.ISSN.1673-4378.2020.02.002","DOIUrl":null,"url":null,"abstract":"Objective \nTo explore the effects of parecoxib sodium on the inflammatory factors of septic patients induced by abdominal infection and the function of intestinal barrier. \n \n \nMethods \nClinical data were collected from 97 septic patients who were admitted into Nanjing Integrated Traditional Chinese and Western Medicine Hospital due to abdominal infection and received treatment from April, 2015 to October, 2017. According to the random number table method, the patients were divided into two groups: a treatment group (parecoxib, n=50) and a control group (normal saline, n=47). Both groups were compared for general information, I-fatty acid-binding protein (I-FABP), diamine oxidase (DAO), D-lactate (D-Lac), interleukin-6 (IL-6), C reactive protein (CRP) and tumor necrosis factor-α (TNF-α) before and after treatment, and morality after treatment. \n \n \nResults \nThere was no statistical difference in general information between the two groups (P>0.05). No statistical difference was found in intestinal barrier function and inflammatory indicators in both groups before treatment (P>0.05). The two groups presented remarkably reduced levels of I-FABP, DAO and D-Lac after treatment, compared with their levels before treatment, and the levels of I-FABP, DAO and D-Lac in the treatment group were obviously lower than those in the control group (P<0.05). The two groups presented remarkably reduced levels of IL-6, CRP and TNF-α after treatment, compared with their levels before treatment, and the levels of IL-6, CRP and TNF-α in the treatment group were obviously lower than those in the control group (P<0.05). The 28-day mortality of the treatment group (12.0%, 6/50) was obviously lower than that of the control group (31.9%, 14/47) (χ2=4.683, P=0.03). \n \n \nConclusions \nParecoxib sodium can relieve inflammatory reaction, while protecting the intestinal barrier function in septic patients, with good safety. \n \n \nKey words: \nParecoxib; Sepsis; Intestinal barrier; Inflammatory reaction","PeriodicalId":13847,"journal":{"name":"国际麻醉学与复苏杂志","volume":"41 1","pages":"134-137"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of parecoxib sodium on the intestinal barrier function of septic patients induced by abdominal infection\",\"authors\":\"Weiwei Wu, Yue-Jun Xu, Yue Zou, Caixiang Jin\",\"doi\":\"10.3760/CMA.J.ISSN.1673-4378.2020.02.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo explore the effects of parecoxib sodium on the inflammatory factors of septic patients induced by abdominal infection and the function of intestinal barrier. \\n \\n \\nMethods \\nClinical data were collected from 97 septic patients who were admitted into Nanjing Integrated Traditional Chinese and Western Medicine Hospital due to abdominal infection and received treatment from April, 2015 to October, 2017. According to the random number table method, the patients were divided into two groups: a treatment group (parecoxib, n=50) and a control group (normal saline, n=47). Both groups were compared for general information, I-fatty acid-binding protein (I-FABP), diamine oxidase (DAO), D-lactate (D-Lac), interleukin-6 (IL-6), C reactive protein (CRP) and tumor necrosis factor-α (TNF-α) before and after treatment, and morality after treatment. \\n \\n \\nResults \\nThere was no statistical difference in general information between the two groups (P>0.05). No statistical difference was found in intestinal barrier function and inflammatory indicators in both groups before treatment (P>0.05). The two groups presented remarkably reduced levels of I-FABP, DAO and D-Lac after treatment, compared with their levels before treatment, and the levels of I-FABP, DAO and D-Lac in the treatment group were obviously lower than those in the control group (P<0.05). The two groups presented remarkably reduced levels of IL-6, CRP and TNF-α after treatment, compared with their levels before treatment, and the levels of IL-6, CRP and TNF-α in the treatment group were obviously lower than those in the control group (P<0.05). The 28-day mortality of the treatment group (12.0%, 6/50) was obviously lower than that of the control group (31.9%, 14/47) (χ2=4.683, P=0.03). \\n \\n \\nConclusions \\nParecoxib sodium can relieve inflammatory reaction, while protecting the intestinal barrier function in septic patients, with good safety. \\n \\n \\nKey words: \\nParecoxib; Sepsis; Intestinal barrier; Inflammatory reaction\",\"PeriodicalId\":13847,\"journal\":{\"name\":\"国际麻醉学与复苏杂志\",\"volume\":\"41 1\",\"pages\":\"134-137\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际麻醉学与复苏杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-4378.2020.02.002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际麻醉学与复苏杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-4378.2020.02.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的探讨帕瑞昔布钠对脓毒症腹腔感染患者炎性因子及肠道屏障功能的影响。方法收集2015年4月至2017年10月南京市中西医结合医院收治的97例因腹部感染接受治疗的脓毒症患者的临床资料。根据随机数字表法将患者分为两组:治疗组(parecoxib, n=50)和对照组(生理盐水,n=47)。比较两组治疗前后的一般信息、i -脂肪酸结合蛋白(I-FABP)、二胺氧化酶(DAO)、d-乳酸(D-Lac)、白细胞介素-6 (IL-6)、C反应蛋白(CRP)、肿瘤坏死因子-α (TNF-α),以及治疗后的道德指标。结果两组一般资料比较,差异无统计学意义(P < 0.05)。治疗前两组患者肠道屏障功能及炎症指标比较,差异均无统计学意义(P < 0.05)。两组患者治疗后I-FABP、DAO、D-Lac水平均较治疗前显著降低,且治疗组I-FABP、DAO、D-Lac水平明显低于对照组(P<0.05)。两组患者治疗后IL-6、CRP、TNF-α水平均较治疗前显著降低,且治疗组IL-6、CRP、TNF-α水平明显低于对照组(P<0.05)。治疗组28天死亡率(12.0%,6/50)明显低于对照组(31.9%,14/47)(χ2=4.683, P=0.03)。结论帕瑞昔布钠可减轻脓毒症患者的炎症反应,同时保护肠道屏障功能,安全性好。关键词:帕累昔布;脓毒症;肠道屏障;炎症反应
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Effects of parecoxib sodium on the intestinal barrier function of septic patients induced by abdominal infection
Objective To explore the effects of parecoxib sodium on the inflammatory factors of septic patients induced by abdominal infection and the function of intestinal barrier. Methods Clinical data were collected from 97 septic patients who were admitted into Nanjing Integrated Traditional Chinese and Western Medicine Hospital due to abdominal infection and received treatment from April, 2015 to October, 2017. According to the random number table method, the patients were divided into two groups: a treatment group (parecoxib, n=50) and a control group (normal saline, n=47). Both groups were compared for general information, I-fatty acid-binding protein (I-FABP), diamine oxidase (DAO), D-lactate (D-Lac), interleukin-6 (IL-6), C reactive protein (CRP) and tumor necrosis factor-α (TNF-α) before and after treatment, and morality after treatment. Results There was no statistical difference in general information between the two groups (P>0.05). No statistical difference was found in intestinal barrier function and inflammatory indicators in both groups before treatment (P>0.05). The two groups presented remarkably reduced levels of I-FABP, DAO and D-Lac after treatment, compared with their levels before treatment, and the levels of I-FABP, DAO and D-Lac in the treatment group were obviously lower than those in the control group (P<0.05). The two groups presented remarkably reduced levels of IL-6, CRP and TNF-α after treatment, compared with their levels before treatment, and the levels of IL-6, CRP and TNF-α in the treatment group were obviously lower than those in the control group (P<0.05). The 28-day mortality of the treatment group (12.0%, 6/50) was obviously lower than that of the control group (31.9%, 14/47) (χ2=4.683, P=0.03). Conclusions Parecoxib sodium can relieve inflammatory reaction, while protecting the intestinal barrier function in septic patients, with good safety. Key words: Parecoxib; Sepsis; Intestinal barrier; Inflammatory reaction
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
7758
期刊最新文献
Research progress on cholinergic anti-inflammatory pathway in acute respiratory distress syndrome Accuracy of invasive systolic pressure variation in monitoring the volume responsiveness of patients under pneumoperitoneum Research progress on blood-brain barrier damage in the pathogenesis of postoperative delirium Comparison of the application of cuffed or uncuffed endotracheal tubes in full-term newborns undergoing congenital intestinal atresia surgery Research progress on the clinical application of apneic oxygenation technology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1